11.3 Psychopharmacology & Crisis Intervention

11.3 Psychopharmacology & Crisis Intervention

Psychopharmacology and psychiatric crisis management constitute essential clinical competencies for registered nurses practicing under Department of Health Abu Dhabi standards. Psychotropic medications exert profound biochemical effects across central neurotransmitter systems, necessitating vigilant monitoring for therapeutic efficacy, narrow therapeutic indices, and life-threatening adverse drug reactions. Concurrently, managing behavioral agitation and psychiatric emergencies requires mastery of verbal de-escalation techniques, environmental modification, and the rigorous legal and ethical protocols governing restraint and seclusion as measures of absolute last resort.

---

Antidepressant Pharmacotherapy & Serotonin Toxicity

Antidepressants modify synaptic concentrations of serotonin (5-HT), norepinephrine (NE), and dopamine (DA). Selecting and monitoring these agents requires understanding their distinct safety profiles and pharmacological interactions.

1. Selective Serotonin Reuptake Inhibitors (SSRIs)

• Agents: Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram.
• Mechanism: Selectively inhibit presynaptic serotonin reuptake transporters (SERT), prolonging 5-HT receptor stimulation.
• Adverse Effects: Nausea, headache, insomnia, initial agitation, and sexual dysfunction (anorgasmia, erectile dysfunction in up to 40% of patients). Syndrome of Inappropriate Antidiuretic Hormone (SIADH) and hyponatremia occur in elderly patients. Mild antiplatelet action increases gastrointestinal bleeding risk when combined with NSAIDs or anticoagulants.
• Boxed Warning: Increased risk of suicidal ideation and behaviors in children, adolescents, and young adults up to age 24 during initial titration.

2. Serotonin Syndrome (Serotonergic Toxicity)

Serotonin syndrome is a potentially fatal toxidrome resulting from excessive central and peripheral 5-HT2A and 5-HT1A receptor stimulation. It is typically triggered by combining multiple serotonergic agents (e.g., SSRIs/SNRIs with MAOIs, tricyclic antidepressants, St. John's Wort, tramadol, meperidine, linezolid, dextromethorphan, or triptans).

• Clinical Diagnostic Triad:
  1. Neuromuscular Hyperactivity: Spontaneous, inducible, or ocular clonus (the most specific physical sign), hyperreflexia (exaggerated deep tendon reflexes, typically more pronounced in lower extremities), bilateral Babinski signs, shivering, and tremors.
  2. Autonomic Instability: Marked hyperthermia (> 38.5°C to 41°C in severe cases), profuse diaphoresis, flushing, sinus tachycardia, labile hypertension, mydriasis (dilated pupils), and hyperactive bowel sounds with watery diarrhea.
  3. Altered Mental Status: Severe agitation, pacing, excitement, confusion, delirium, and coma.
• Emergency Nursing Interventions:
  • Immediately discontinue all serotonergic agents.
  • Initiate supportive airway and hemodynamic stabilization, aggressive intravenous crystalloid hydration, and active external cooling (cooling blankets, ice packs to groin/axillae).
  • Administer intravenous benzodiazepines (lorazepam, diazepam) to control psychomotor agitation, blunt autonomic hyperactivity, and suppress muscle clonus.
  • Administer the specific 5-HT receptor antagonist Cyproheptadine as prescribed for moderate to severe toxicity.
  • Mandatory Washout Periods: When transitioning between an SSRI and an MAOI, a minimum 14-day washout period is strictly required. For fluoxetine, due to the exceptionally long elimination half-life of its active metabolite norfluoxetine (7 to 15 days), a minimum 5-week washout period is mandatory prior to initiating an MAOI.

3. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

• Agents: Venlafaxine, Duloxetine, Desvenlafaxine.
• Mechanism: Inhibit both serotonin and norepinephrine reuptake.
• Adverse Effects: Shares SSRI side effects plus dose-dependent diastolic hypertension and tachycardia secondary to noradrenergic stimulation. Blood pressure must be monitored routinely. Duloxetine carries indications for diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain.

4. Tricyclic Antidepressants (TCAs)

• Agents: Amitriptyline, Nortriptyline, Imipramine, Doxepin.
• Mechanism: Inhibit 5-HT and NE reuptake, but also exert potent antagonist actions at muscarinic acetylcholine, alpha-1 adrenergic, and histamine H1 receptors.
• Adverse Profiles: Pronounced anticholinergic side effects (dry mouth, blurred vision, urinary retention, severe constipation, tachycardia), orthostatic hypotension, and heavy sedation.
• Lethality in Overdose & Cardiotoxicity: TCAs possess a low therapeutic index; overdose is frequently fatal due to blockade of cardiac fast sodium channels. Electrocardiogram (ECG) demonstrates widened QRS (> 100 ms), prolonged QTc, right bundle branch block, ventricular tachycardia, torsades de pointes, and profound refractory hypotension.
• Emergency Antidote: Intravenous Sodium Bicarbonate (1 to 2 mEq/kg) is administered for TCA-induced QRS prolongation (> 100 ms) or ventricular dysrhythmias. Sodium bicarbonate alkalinizes serum pH to 7.45–7.55 (reducing sodium-channel binding) and delivers a high extracellular sodium load that overcomes myocardial fast sodium channel blockade.

5. Monoamine Oxidase Inhibitors (MAOIs)

• Agents: Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline (transdermal).
• Mechanism: Irreversibly inhibit monoamine oxidase enzymes (MAO-A and MAO-B), blocking the enzymatic catabolism of serotonin, norepinephrine, and dopamine.
• Dietary Tyramine & Hypertensive Crisis: Ingesting dietary tyramine (normally degraded by intestinal MAO-A) allows tyramine to enter systemic circulation and displace massive amounts of stored norepinephrine from presynaptic vesicles into synaptic clefts, causing severe arterial vasoconstriction.
• Strict Dietary Restrictions: Complete avoidance of tyramine-rich foods: aged cheeses (cheddar, parmesan, Roquefort), cured/aged/smoked meats (salami, pepperoni), pickled herring, tap/draft beers, unpasteurized ales, red wine, soy sauce, tofu, fava beans, broad beans, Marmite, and overripe bananas/avocados.
• Manifestations of Hypertensive Crisis: Sudden, explosive, throbbing occipital headache radiating frontally, palpitations, neck stiffness, severe hypertension (systolic BP > 180 mmHg), nausea, vomiting, dilated pupils, and intracranial hemorrhage risk.
• Emergency Treatment: Immediate cessation of the MAOI, intravenous administration of phentolamine (alpha-adrenergic blocker), labetalol, or sodium nitroprusside, and continuous invasive hemodynamic monitoring.

---

Mood Stabilizers: Lithium & Anticonvulsants

Mood stabilizers prevent and treat manic and depressive episodes in bipolar disorder.

Lithium Carbonate

Lithium carbonate remains the gold-standard mood stabilizer for acute mania, bipolar maintenance, and long-term suicide risk reduction.

• Therapeutic Serum Levels:
  • Acute Mania Target: 0.8 to 1.2 mEq/L (up to 1.5 mEq/L in severe inpatient mania).
  • Long-Term Maintenance: 0.6 to 1.0 mEq/L.
  • Timing of Blood Draws: Serum levels must be drawn precisely as a 12-hour trough (12 hours after the preceding evening dose, prior to the morning dose).
• Spectrum of Lithium Toxicity:
  • Mild to Moderate Toxicity (1.5 to 2.0 mEq/L): Coarse hand tremors (differentiated from benign fine postural tremors), persistent nausea, vomiting, severe watery diarrhea, lethargy, muscle weakness, and hyperactive deep tendon reflexes.
  • Moderate to Severe Toxicity (2.0 to 2.5 mEq/L): Marked ataxia, slurred speech, giddiness, blurred vision, tinnitus, clonic muscle twitches, and profound psychomotor confusion.
  • Life-Threatening Toxicity (> 2.5 mEq/L): Generalized seizures, oliguric acute kidney injury, cardiac dysrhythmias, hypotension, stupor, coma, and cardiovascular collapse.
• Physiological Sodium Balance & Renal Handling: Lithium is an inorganic monovalent cation handled by the renal proximal tubules identically to sodium. When systemic sodium is depleted (hyponatremia, vomiting, diaphoresis, strict low-sodium diets) or when dehydration occurs, the proximal tubules reabsorb increased amounts of lithium in an attempt to retain sodium, triggering rapid lithium toxicity. Instruct patients to maintain consistent dietary sodium intake and drink 2 to 3 liters of fluid daily.
• Severe Drug Interactions:
  • NSAIDs (ibuprofen, naproxen, celecoxib): Inhibit renal prostaglandins and reduce renal lithium clearance, increasing serum levels and toxicity risk. The effect varies; avoid unsupervised NSAID use and monitor lithium if co-prescription is necessary (acetaminophen has no comparable lithium interaction).
  • Thiazide Diuretics (hydrochlorothiazide): Deplete sodium at the distal tubule, causing compensatory proximal tubule sodium and lithium reabsorption, precipitating toxicity.
  • ACE Inhibitors & ARBs: Impair renal filtration and dramatically elevate serum lithium.
• Baseline & Serial Organ Monitoring: Renal function tests (BUN, serum creatinine, urine specific gravity) to monitor for nephrogenic diabetes insipidus and chronic tubulointerstitial nephropathy; Thyroid function tests (TSH, free T4) to screen for lithium-induced goiter and hypothyroidism; and serum pregnancy testing (lithium is teratogenic, associated with Ebstein's cardiac anomaly).
• Treatment of Severe Toxicity: Stop lithium, obtain urgent toxicology/nephrology advice, monitor ECG/renal function and restore volume with IV 0.9% saline as appropriate. Dialysis depends on symptoms, renal function and serial levels—not a universal 2.5 mEq/L threshold. EXTRIP recommends dialysis for impaired kidney function with lithium >4 mEq/L, or decreased consciousness, seizures or life-threatening dysrhythmias at any level; it also suggests dialysis for levels >5 mEq/L, significant confusion or prolonged predicted clearance.

Anticonvulsant Mood Stabilizers

1. Valproic Acid / Divalproex Sodium: Therapeutic level: 50 to 125 mcg/mL. Boxed warnings for fatal hepatotoxicity (monitor baseline and serial liver function tests: AST, ALT, bilirubin), acute pancreatitis (patient must immediately report severe abdominal pain radiating to the back), and teratogenicity (neural tube defects such as spina bifida).
2. Carbamazepine: Therapeutic level: 4 to 12 mcg/mL. Boxed warnings for aplastic anemia and agranulocytosis (monitor complete blood counts regularly; patient must report fever, chills, sore throat, or petechiae) and severe dermatologic reactions (Stevens-Johnson Syndrome, especially in patients carrying the HLA-B*1502 allele).
3. Lamotrigine: Primarily utilized for bipolar depression maintenance. Major clinical safety concern: development of life-threatening severe cutaneous reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Dosing must follow a slow, stepwise titration; the nurse must instruct the patient to withhold the drug and contact the clinic immediately at the first emergence of any skin rash or mucosal lesion.

---

Antipsychotic Agents & Critical Emergencies

Antipsychotics (neuroleptics) treat schizophrenia, acute psychotic agitation, bipolar mania, and treatment-resistant mood disorders.

First-Generation Antipsychotics (FGAs; Typical)

• Agents: Haloperidol, Fluphenazine, Chlorpromazine.
• Mechanism: Potent antagonism of postsynaptic dopamine D2 receptors in the mesolimbic and nigrostriatal tracts.
• Extrapyramidal Symptoms (EPS):
  1. Acute Dystonia (Hours to Days): Severe, painful, sustained spastic muscle contractions of the neck (torticollis), jaw (trismus), tongue, eyes (oculogyric crisis), or larynx (laryngospasm causing airway compromise). Emergency Treatment: Immediate intramuscular or intravenous injection of Diphenhydramine (25 to 50 mg) or Benztropine (1 to 2 mg).
  2. Akathisia (Days to Weeks): Subjective motor restlessness, inner tension, and an irresistible urge to move (pacing, shifting weight, foot tapping). Often misdiagnosed as worsening psychotic agitation. Managed with beta-blockers (propranolol) or benzodiazepines.
  3. Pseudoparkinsonism (Weeks to Months): Triad of bradykinesia, resting tremor, cogwheel rigidity, mask-like facies, and shuffling festinating gait. Managed with oral anticholinergics (benztropine, trihexyphenidyl) or amantadine.
  4. Tardive Dyskinesia (TD; Months to Years): Involuntary, rhythmic, choreoathetoid movements of the tongue (protrusion, curling), lips (smacking, puckering), jaw (chewing), face (grimacing), and extremities. Often irreversible. Screened every 3 to 6 months using the Abnormal Involuntary Movement Scale (AIMS). Discontinue offending FGA; switch to an atypical antipsychotic (clozapine); treated with vesicular monoamine transporter 2 (VMAT2) inhibitors (valbenazine, deutetrabenazine).

Neuroleptic Malignant Syndrome (NMS)

Neuroleptic Malignant Syndrome is a medical emergency associated with dopamine-receptor blockade or abrupt withdrawal of dopaminergic treatment, such as antiparkinsonian medicines.

• Hallmark Diagnostic Tetrad:
  1. Severe 'Lead-Pipe' Muscle Rigidity: Resistance to passive limb flexion and extension across all muscle groups.
  2. Hyperpyrexia: Extreme hyperthermia, with body temperatures typically exceeding 40.0°C (104.0°F).
  3. Autonomic Instability: Profuse diaphoresis, severe sinus tachycardia, marked labile blood pressure fluctuations, tachypnea, and cardiac dysrhythmias.
  4. Altered Mental Status: Confusion, agitation, mutism, delirium, progressing rapidly to stupor and coma.
• Laboratory Biomarkers: Massive elevation of Creatine Kinase (CK > 1,000 to 50,000+ U/L) reflecting severe rhabdomyolysis; leukocytosis (WBC 15,000 to 30,000/uL); elevated serum creatinine, metabolic acidosis, and myoglobinuria.
• Emergency Interventions:
  • Immediately discontinue all antipsychotic medications.
  • Activate rapid response / transfer to the Intensive Care Unit (ICU).
  • Aggressive external cooling (cooling blankets, ice packs to neck, axillae, groin) and IV crystalloids to maintain urine output >= 100 mL/hr to prevent myoglobinuric acute tubular necrosis.
  • Pharmacotherapy: Administer Dantrolene (a direct skeletal muscle relaxant that blocks sarcoplasmic calcium release) and Bromocriptine (a dopamine D2 receptor agonist that overcomes central dopaminergic blockade).

Second-Generation Antipsychotics (SGAs; Atypical)

• Agents: Clozapine, Olanzapine, Quetiapine, Risperidone, Aripiprazole.
• Mechanism: Most SGAs combine dopamine D2 and serotonin 5-HT2A antagonism; aripiprazole is a D2 partial agonist with 5-HT2A antagonism. EPS and metabolic risks differ between drugs.
• Clozapine & Neutropenia: Clozapine is effective for treatment-resistant schizophrenia and persistent suicidal behavior but can cause severe neutropenia. Obtain baseline ANC and perform regular counts at the frequency required by the approved product and facility monitoring protocol. Usual initiation thresholds are ANC >=1,500/uL, or >=1,000/uL with confirmed benign ethnic/Duffy-null-associated neutrophil counts. ANC 500–999/uL is moderate neutropenia; <500/uL is severe neutropenia. Lower action thresholds apply to confirmed benign ethnic neutropenia. Urgently assess fever or sore throat, obtain an ANC and notify the prescriber/monitoring service. Follow the approved interruption, discontinuation and re-exposure rules; never restart independently.
• Metabolic Syndrome: Clozapine and olanzapine carry the highest weight-gain risk. SGAs, including quetiapine, can also cause dyslipidemia, insulin resistance, type 2 diabetes and diabetic ketoacidosis. Monitor BMI, waist circumference, fasting lipids and glucose at baseline and during treatment.
• Risperidone & Hyperprolactinemia: D2 antagonism increases prolactin; risperidone has a relatively high risk of hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia in males, sexual dysfunction).

---

Table: Psychotropic Medications, Therapeutic Ranges & Critical Monitoring

---

Crisis Intervention, Behavioral De-escalation & Restraint Protocols

Psychiatric crisis intervention follows a graduated, trauma-informed continuum prioritizing verbal de-escalation, environmental calming, and voluntary interventions, reserving physical restraint and seclusion as emergency measures of absolute last resort.

Trauma-Informed Verbal De-escalation Protocols

When a patient demonstrates accelerating behavioral agitation, the nurse must intervene early:

• Maintain Personal & Client Safety: Maintain a physical distance of at least two arm lengths from the patient. Ensure an unblocked physical exit path for both the nurse and the patient. Never turn your back or corner an agitated patient.
• Non-Threatening Physical Posture: Stand at an angle (approx. 45 degrees) rather than squaring off chest-to-chest. Keep hands relaxed and visible, open at waist level. Avoid crossing arms, pointing fingers, or touching an agitated client without consent.
• Calm, Controlled Communication: Speak in a soft, low, calm, unhurried tone. Use short, simple, direct sentences. Acknowledge and validate the patient's emotional distress without validating cognitive distortions ("I can see how frustrated and overwhelmed you feel right now. I am here to help keep you safe").
• Offer Structured Choices: Empower the client by offering concrete, realistic options ("Would you like to walk to the quiet room to sit down, or would you prefer a cup of water out here in the courtyard?").
• Voluntary PRN Pharmacotherapy: Offer prescribed oral anti-anxiety or antipsychotic medication (e.g., oral lorazepam, orally disintegrating olanzapine, or liquid haloperidol) early in the escalation cycle to assist the patient in regaining internal emotional control.

Seclusion and Physical Restraint as Absolute Last Resort

Seclusion (involuntary confinement of a client alone in a room where exit is prevented) and physical restraints (mechanical devices immobilizing a client's extremities) are strictly regulated under DOH Abu Dhabi and international patient safety standards:

1. Legal Indications and Proportionality: UAE Mental Health Law permits restraint or isolation to prevent the patient harming themselves or others, or attacking property. Use the least restrictive, proportionate response after appropriate alternatives have failed; continue de-escalation. Never use either measure for punishment, discipline or staff convenience.
2. Medical Evaluation and Authorization: Obtain psychiatrist authorization and document it on the prescribed form. In an emergency, the attending nurse may initiate restraint or isolation but must immediately notify the psychiatrist to examine the patient and determine its duration. Record the reason, alternatives attempted, authorization and monitoring plan.
3. Separate Duration Controls: UAE Cabinet Resolution 213 of 2025, effective 14 April 2026, limits restraint to 1 continuous hour, renewable after examination and psychiatrist approval. Isolation is limited to 6 continuous hours unless the patient’s condition requires a psychiatrist-approved, documented extension. Do not apply restraint and isolation concurrently. End either measure immediately when its reason ceases, with the required representative and Patients’ Rights Care Committee notifications and documentation.
4. Intensive Nursing Monitoring & Documentation:
   • Continuous 1:1 direct visual observation.
   • Formal clinical assessment documented every 15 minutes: vital signs, neurovascular status of restrained extremities (peripheral pulses, capillary refill, skin color, temperature, motor function), skin integrity under restraint cuffs.
   • Offer fluids, nutrition, range-of-motion limb exercises, and toileting opportunities every 15 to 30 minutes.
5. Immediate Termination Criteria: Stop restraint as soon as the immediate reason for it has ceased. Reassess safety and continue supportive care; release is not conditional on a patient demonstrating obedience to instructions.